{rfName}

Indexed in

License and use

Citations

2

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

De Moner Cervos, NoemiAuthorLledó-Ibáñez GmAuthorEspinosa, GerardAuthor

Share

September 22, 2024
Publications
>
Article
No

Could the IgA isotype provide additional information in systemic sclerosis patients? A retrospective study entailing IgA isotyping in a Mediterranean systemic sclerosis cohort

Publicated to:Clinical And Experimental Rheumatology. 42 (8): 1556-1563 - 2024-08-01 42(8), DOI: 10.55563/clinexprheumatol/qijvcj

Authors: Perez-Isidro, Albert; Lledo-Ibanez, Gema M; de Moner, Noemi; Torradeflot, Maria; Martinez, Maria Jose; Espinosa, Gerard; Campos, Merce Tena; Grundhuber, Maresa; Vinas, Odette; Ruiz-Ortiz, Estibaliz

Affiliations

Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Dept Immunol, Villarroel 170, Barcelona 08036, Spain - Author
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain - Author
Reference Ctr Syst Autoimmune Dis CSUR Spanish Hlt, Barcelona, Spain - Author
Thermo Fisher Sci, Cornella De Llobregat, Spain - Author
Thermo Fisher Sci, Freiburg, Germany - Author
Univ Barcelona, Hosp Clin, Dept Autoimmune Dis, Barcelona, Spain - Author
See more

Abstract

Objective Anti-CENP-B (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RP3) autoantibodies are included in the 2013 SSc-ACR/EULAR classification criteria. The detection of additional autoantibodies is of interest when those are negative. Additionally, we wonder if the IgA isotype might play a role in SSc. The aims of the study were to assess the prevalence of ACA, ATA, RP3, and Ro52 autoantibodies of IgG and IgA isotype and to describe their association with clinical manifestations in a cohort of patients with SSc. Methods Samples from 97 patients with SSc fulfilling the 2013 ACR/EULAR classification criteria, and 50 blood donors were included and tested for IgA and IgG isotypes of ACA, ATA, RP3, and Ro52 by FEIA. Results The prevalence of IgG+IgA isotypes for the same specificity was 62.5%, 82.6%, 80.0%, 36.8%, for ACA, ATA, RP3 and Ro52, respectively. Isolated IgG was present in 35.4%, 13.0%, 20.0% and 42.1% of patients for ACA, ATA, RP3 and Ro52, respectively. Only six patients were isolated IgA for a unique specificity. Clinically, ILD tended to be associated with ATA-IgG and ATA-IgG+IgA, telangiectasias with ACA-IgG+IgA and arthritis with ACA-IgA. Indeed, digital ulcers were more frequent in ATA-IgG patients. Conclusion Most of the patients presented ACA, ATA, or RP3 autoantibodies of IgA isotype in addition to IgG. Regarding clinical relevance, Ro52-IgG+IgA and ACA-IgG had a tendency towards sineSSc phenotype, while ACAIgG+IgA to lcSSc phenotype. Thus, if confirmed, the determination of ACA-IgA could provide a tool to stratify patients according to the cutaneous phenotype.

Keywords

AdultAgedAntibodieAntinuclear antibodyArticleAutoantibodiesAutoantibodyAutoimmune thyroiditisBiological markerBiomarkersBloodBlood donorCalibrationCohort analysisControlled studyDiagnosisDisease durationDna directed rna polymerase iiiDna topoisomeraseDna topoisomerases, type iEnzyme linked immunosorbent assayEpidemiologyFemaleFibrillarinHumanHuman tissueHumansIga autoantibodiesImmunoglobulin aImmunoglobulin classImmunoglobulin gImmunologyInterstitial lung diseasInterstitial lung diseaseInterstitial lung-diseaseLife below waterMajor clinical studyMaleMiddle agedMyelooptic neuropathyMyositisPhenotypePredictive valuePredictive value of testsPrevalenceRetrospective studiesRetrospective studyRna polymeraseRna polymerase iiiScleroderma trialsScleroderma, systemicSystemic lupus erythematosusSystemic sclerosisTopoisomerase-i

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical And Experimental Rheumatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 17/57, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Rheumatology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Rheumatology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-08:

  • WoS: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-08:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 7 (PlumX).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 14 - Conserve and sustainably use the oceans, seas and marine resources for sustainable development, with a probability of 89% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Germany.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Perez-Isidro, Albert) and Last Author (Ruiz-Ortiz, Estibaliz).

the authors responsible for correspondence tasks have been Vinas, Odette and Ruiz-Ortiz, Estibaliz.